Keywords: RXi Pharma, Apthera, Sanofi-Aventis, Genzyme, M&A, Breas cancer vaccine, NeuVax
RXi Pharma to acquire Apthera in stock deal; Sanofi snares Genzyme
Article | 04 April 2011
Privately-held US biotech firm Apthera, which is developing a pipeline of peptide based immune-therapies, has entered into a definitive merger ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
